Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

2013 Genitourinary Cancers Symposium

14 - 16 Feb 2013
Rosen Shingle Creek, Orlando, United States of America
ASCO GU: Current thinking in mCRPC
Dr Howard Scher - Memorial Sloan Kettering Cancer Center, New York
ASCO GU: Current thinking in mCRPC ( Dr Howard Scher - Memorial Sloan Kettering Cancer Center, New York )
1 Mar 2013
ASCO GU: Update on clinical study results presented in mCRPC
Prof Eleni Efstathiou - MD Anderson Cancer Centre, USA
ASCO GU: Update on clinical study results presented in mCRPC ( Prof Eleni Efstathiou - MD Anderson Cancer Centre, USA )
1 Mar 2013
ASCO GU: Comments from the principal investigator of the COU-AA-302 study
Dr Charles Ryan - UCSF Cancer Center, San Francisco, California, USA
ASCO GU: Comments from the principal investigator of the COU-AA-302 study ( Dr Charles Ryan - UCSF Cancer Center, San Francisco, California, USA )
1 Mar 2013
ASCO GU: review of data presented in mCRPC
Dr Kurt Miller – University of Berlin, Germany
ASCO GU: review of data presented in mCRPC ( Dr Kurt Miller – University of Berlin, Germany )
26 Feb 2013
ASCO GU: Review of new data presented in mCRPC
Dr Karim Fizazi - Institut Gustave Roussy, France
ASCO GU: Review of new data presented in mCRPC ( Dr Karim Fizazi - Institut Gustave Roussy, France )
26 Feb 2013
Overtreatment of low risk prostate cancer: incidence in USA, cost, complications...
Dr Ayal Aizer - Dana Farber Cancer Centre, Boston, USA
Overtreatment of low risk prostate cancer: incidence in USA, cost, complications and implications ( Dr Ayal Aizer - Dana Farber Cancer Centre, Boston, USA )
26 Feb 2013
Effect of therapeutic anticoagulation on overall survival in men receiving docet...
Dr Caroline Pratz - Kimmel Cancer Center, Johns Hopkins University, Baltimore
Effect of therapeutic anticoagulation on overall survival in men receiving docetaxel for mCRPC ( Dr Caroline Pratz - Kimmel Cancer Center, Johns Hopkins University, Baltimore )
25 Feb 2013
Enzalutamide monotherapy: Phase II study results in patients with hormone-naive ...
Dr Bertrand Tombal - Catholic University of Louvain, Belgium
Enzalutamide monotherapy: Phase II study results in patients with hormone-naive prostate cancer ( Dr Bertrand Tombal - Catholic University of Louvain, Belgium )
25 Feb 2013
Gleason upgrading with time in a large, active surveillance cohort with long-ter...
Dr Andrew Loblaw - Sunnybrook Health Sciences Centre, Toronto, Canada
Gleason upgrading with time in a large, active surveillance cohort with long-term follow-up ( Dr Andrew Loblaw - Sunnybrook Health Sciences Centre, Toronto, Canada )
25 Feb 2013
Pelvic radiotherapy and androgen blockade for high risk prostate cancer
Dr Abdenour Nabid - Sherbrooke University, Quebec, Canada
Pelvic radiotherapy and androgen blockade for high risk prostate cancer ( Dr Abdenour Nabid - Sherbrooke University, Quebec, Canada )
25 Feb 2013
TIVO 1 study shows tivozanib an option for renal cell carcinoma
Dr Robert Motzer - Memorial Sloan Kettering Cancer Centre, New York, USA
TIVO 1 study shows tivozanib an option for renal cell carcinoma ( Dr Robert  Motzer - Memorial Sloan Kettering Cancer Centre, New York, USA )
25 Feb 2013
Chemo-radiotherapy for bladder cancer
Prof Nick James - University of Birmingham, UK
Chemo-radiotherapy for bladder cancer ( Prof Nick James	 - University of Birmingham, UK )
25 Feb 2013
Prediction of relapse in stage I nonseminomatous germ cell tumors by CXCL12
Dr Duncan Gilbert - Sussex Cancer Centre, Brighton , UK
Prediction of relapse in stage I nonseminomatous germ cell tumors by CXCL12 ( Dr Duncan Gilbert - Sussex Cancer Centre, Brighton	, UK )
25 Feb 2013